"165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials" by Philip J Mease

Article

165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials

Rheumatology (2018)

Philip J Mease, University of Washington
Helena Marzo-Ortega, University of Leeds
Airi Poder
Filip Van den Bosch, Ghent University Hospital
Jurgen Wollenhaupt, Hochschule Hannover
Eric Lespessailles, University of Orléans
Lichen Teng, Celgene
Stephen Hall, Monash University

Link

Disciplines

Publication Date

April 1, 2018

DOI

10.1093/rheumatology/key075.389

Citation Information

Philip J Mease, Helena Marzo-Ortega, Airi Poder, Filip Van den Bosch, et al.. "165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials" Rheumatology Vol. 57 (2018)
Available at: http://works.bepress.com/philip-mease/9/